Physician Experiences and Understanding of Genomic Sequencing in Oncology
- PMID: 28840409
- PMCID: PMC5810555
- DOI: 10.1007/s10897-017-0134-3
Physician Experiences and Understanding of Genomic Sequencing in Oncology
Abstract
The amount of information produced by genomic sequencing is vast, technically complicated, and can be difficult to interpret. Appropriately tailoring genomic information for non-geneticists is an essential next step in the clinical use of genomic sequencing. To initiate development of a framework for genomic results communication, we conducted eighteen qualitative interviews with oncologists who had referred adult cancer patients to a matched tumor-normal tissue genomic sequencing study. In our qualitative analysis, we found varied levels of clinician knowledge relating to sequencing technology, the scope of the tumor genomic sequencing study, and incidental germline findings. Clinicians expressed a perceived need for more genetics education. Additionally, they had a variety of suggestions for improving results reports and possible resources to aid in results interpretation. Most clinicians felt genetic counselors were needed when incidental germline findings were identified. Our research suggests that more consistent genetics education is imperative in ensuring the proper utilization of genomic sequencing in cancer care. Clinician suggestions for results interpretation resources and results report modifications could be used to improve communication. Clinicians' perceived need to involve genetic counselors when incidental germline findings were found suggests genetic specialists could play a critical role in ensuring patients receive appropriate follow-up.
Keywords: Cancer genomics; Genomics; Individualized medicine; Medical oncology; Physicians.
Conflict of interest statement
All other authors declare no conflict of interest.
Figures
References
-
- American Society of Clinical Oncology. New Cigna Policy on Cancer Genetic Testing Poses Risks to High Quality Cancer Care. ASCO; 2013. http://www.asco.org/advocacy-policy/asco-in-action/new-cigna-policy-canc.... Accessed April 16 2017.
-
- Behrendt CE, Hurria A, Tumyan L, Niland JC, Mortimer JE. Socioeconomic and clinical factors are key to uncovering disparity in accrual onto therapeutic trials for breast cancer. Journal of the National Comprehensive Cancer Network : JNCCN. 2014;12(11):1579–85. http://www.ncbi.nlm.nih.gov/pubmed/25361805. Accessed 16 April 2017. - PMC - PubMed
-
- Bell RA, McDermott H, Fancher TL, Green MJ, Day FC, Wilkes MS. Impact of a Randomized Controlled Educational Trial to Improve Physician Practice Behaviors Around Screening for Inherited Breast Cancer. Journal of General Internal Medicine. 2015;30(3):334–341. doi: 10.1007/s11606-014-3113-5. - DOI - PMC - PubMed
-
- Bombard Y, Bach PB, Offit K. Translating genomics in cancer care. Journal of the National Comprehensive Cancer Network : JNCCN. 2013;11(11):1343–53. http://www.ncbi.nlm.nih.gov/pubmed/24225968. Accessed 16 April 2017. - PubMed
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
